Insider Selling: Halozyme Therapeutics (NASDAQ:HALO) CEO Sells 20,000 Shares of Company Stock

Halozyme Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Halozyme CEO Helen Torley sold 20,000 shares at an average $98.38, worth about $1.97 million, under a pre-arranged Rule 10b5-1 trading plan. She retained 767,780 shares after the sale.
  • Torley has also made several recent 20,000-share sales, including one the prior week at $100.38. HALO shares traded at $96.50 on Monday, down $3.77.
  • Halozyme’s latest quarter beat analyst estimates, with EPS of $2.39 and revenue up 39.1% year over year. Analysts’ consensus rating was Hold, with an average price target of $108.18.
  • Five stocks we like better than Halozyme Therapeutics.

Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) CEO Helen Torley sold 20,000 shares of the business's stock in a transaction on Monday, November 16th. The shares were sold at an average price of $98.38, for a total transaction of $1,967,600.00. Following the sale, the chief executive officer owned 767,780 shares of the company's stock, valued at approximately $75,534,196.40. This represents a 2.54% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Helen Torley also recently made the following trade(s):

  • On Friday, November 13th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $100.38, for a total transaction of $2,007,600.00.
  • On Tuesday, October 6th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $109.58, for a total transaction of $2,191,600.00.
  • On Thursday, October 8th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $109.40, for a total value of $2,188,000.00.
  • On Wednesday, September 9th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $107.43, for a total transaction of $2,148,600.00.
  • On Friday, September 11th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $107.24, for a total transaction of $2,144,800.00.
  • On Tuesday, August 18th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $104.18, for a total value of $2,083,600.00.

Halozyme Therapeutics Price Performance

HALO traded down $3.77 on Monday, hitting $96.50. 2,088,290 shares of the company's stock traded hands, compared to its average volume of 2,352,912. The company's 50 day simple moving average is $114.29 and its 200-day simple moving average is $85.63. The company has a current ratio of 3.88, a quick ratio of 3.60 and a debt-to-equity ratio of 13.50. Halozyme Therapeutics, Inc. has a one year low of $61.22 and a one year high of $134.00. The firm has a market cap of $11.00 billion, a price-to-earnings ratio of 18.07, a P/E/G ratio of 0.38 and a beta of 0.92.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its quarterly earnings results on Thursday, November 5th. The biopharmaceutical company reported $2.39 earnings per share for the quarter, topping the consensus estimate of $2.30 by $0.09. Halozyme Therapeutics had a return on equity of 751.81% and a net margin of 26.93%. The business had revenue of $492.97 million during the quarter, compared to the consensus estimate of $491.63 million. During the same period in the prior year, the company posted $1.72 EPS. The firm's revenue for the quarter was up 39.1% compared to the same quarter last year. As a group, research analysts anticipate that Halozyme Therapeutics, Inc. will post 8.34 EPS for the current year.

Institutional Investors Weigh In On Halozyme Therapeutics

A number of hedge funds have recently bought and sold shares of HALO. Thoroughbred Financial Services LLC raised its holdings in shares of Halozyme Therapeutics by 0.4% in the third quarter. Thoroughbred Financial Services LLC now owns 22,336 shares of the biopharmaceutical company's stock worth $2,465,000 after buying an additional 100 shares during the period. Mather Group LLC. grew its position in Halozyme Therapeutics by 48.9% in the 3rd quarter. Mather Group LLC. now owns 414 shares of the biopharmaceutical company's stock valued at $46,000 after acquiring an additional 136 shares during the last quarter. North Dakota State Investment Board increased its stake in Halozyme Therapeutics by 4.3% in the third quarter. North Dakota State Investment Board now owns 3,598 shares of the biopharmaceutical company's stock worth $397,000 after purchasing an additional 147 shares during the period. CoreCap Advisors LLC increased its stake in Halozyme Therapeutics by 98.0% in the third quarter. CoreCap Advisors LLC now owns 303 shares of the biopharmaceutical company's stock worth $33,000 after purchasing an additional 150 shares during the period. Finally, Fifth Third Wealth Advisors LLC increased its stake in Halozyme Therapeutics by 3.5% in the third quarter. Fifth Third Wealth Advisors LLC now owns 4,515 shares of the biopharmaceutical company's stock worth $498,000 after purchasing an additional 151 shares during the period. Hedge funds and other institutional investors own 97.79% of the company's stock.

Analyst Ratings Changes

A number of analysts have issued reports on HALO shares. Zacks Research downgraded shares of Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Wednesday, November 11th. Leerink Partners lowered Halozyme Therapeutics from an "outperform" rating to a "hold" rating and raised their price objective for the company from $110.00 to $117.00 in a research report on Friday, November 6th. HC Wainwright lifted their target price on Halozyme Therapeutics from $115.00 to $130.00 and gave the stock a "buy" rating in a report on Wednesday, October 7th. Wall Street Zen cut Halozyme Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Saturday, November 7th. Finally, Weiss Ratings upgraded Halozyme Therapeutics from a "buy (b)" rating to a "buy (b+)" rating in a research report on Monday, November 9th. Seven equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $108.18.

View Our Latest Analysis on Halozyme Therapeutics

Halozyme Therapeutics Company Profile

(Get Free Report)

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing drug-delivery technologies and medicines. Its ENHANZE platform uses a recombinant human hyaluronidase enzyme, rHuPH20, to temporarily modify tissue under the skin and help enable the subcutaneous administration of certain biologic medicines that might otherwise require intravenous infusion. Halozyme licenses ENHANZE to pharmaceutical and biotechnology partners, which use the technology in their own products. The company also markets Hylenex recombinant, a hyaluronidase product used to facilitate the dispersion and absorption of other injected medicines and fluids.

Featured Articles

Insider Buying and Selling by Quarter for Halozyme Therapeutics (NASDAQ:HALO)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Halozyme Therapeutics Right Now?

Before you consider Halozyme Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Halozyme Therapeutics wasn't on the list.

While Halozyme Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines